Article

Gastrointestinal adverse events associated with Riociguat: A pharmacovigilance study based on FDA adverse event reporting system

2026-06-18

Abstract excerpt

<title>Abstract</title> <p>Background Riociguat, a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), is frequently associated with gastrointestinal adverse events (GI AEs). However, comprehensive real-world evaluations focusing specifically on GI AEs remain limited. Methods FAERS reports from the third quarter of 20...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 58a3c3c3-4e77-56f9-9948-048e546f150f
DOI: 10.21203/rs.3.rs-9681718/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Gastrointestinal adverse events associated with Riociguat: A pharmacovigilance study based on FDA adverse event reporting systemDOI 10.21203/rs.3.rs-9681718/v1Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

Real-world pharmacovigilance study of voclosporin based on FAERS and VigiBaseSemantic proximity Read

Adverse event analysis and signal detection of calcitonin gene-related peptide inhibitors using the FDA Adverse Event Reporting System databaseSemantic proximity Read

A disproportionate analysis of novel oral anticoagulants in the overall and pediatric populations: a pharmacovigilance study based on FDA Adverse Event Reporting System databaseSemantic proximity Read

Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Safety assessment of S-1: Real-world adverse event analysis from the FAERS databaseSemantic proximity Read

Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Pharmacovigilance analysis of inclisiran:a real-world assessment based on the FAERS databaseSemantic proximity Read

Pharmacovigilance Insights into Gastrointestinal Adverse Events of JAK Inhibitors: FAERS Signal Detection with Clinical and Pharmacological ImplicationseSemantic proximity Read

Cross-Database Analysis of Fruquintinib-Associated adverse events: Insights from FAERS and VigiAccess databasesSemantic proximity Read

Infliximab-associated Gastrointestinal Obstruction: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (2004-2024)Semantic proximity Read

Characterizing Gene Therapy Medicinal Products Post-Marketing Safety Reports based on WHO Pharmacovigilance Database, VigiBaseSemantic proximity Read